Proactive Investors - Run By Investors For Investors

Botanix Pharmaceuticals concludes successful atopic dermatitis study

BTX 1204 was effective at reducing the key signs and symptoms of atopic dermatitis.
a woman scratching her skin
Top line data indicates BTX 1204 was well-tolerated

Botanix Pharmaceuticals Ltd (ASX:BOT) has successfully completed a vehicle (placebo) controlled phase Ib study of BTX 1204 in patients with mild to moderate atopic dermatitis.

BTX 1204 is a novel topical formulation of synthetic cannabidiol that utilises Botanix’ proprietary drug delivery system Permetrex.

Twice as effective as the placebo

Top line data indicates BTX 1204 was well-tolerated as there were no significant adverse effects, or reports of skin irritation during the study.

Importantly, BTX 1204 was effective at reducing the key signs and symptoms of atopic dermatitis after only four weeks of treatment

After four weeks of treatment, 35% of patients receiving BTX 1204 achieved treatment success, compared to only 18% of patients who received the vehicle.

Potential new treatment option for atopic dermatitis

About 18 to 25 million people in the United States suffer from atopic dermatitis, including between 8% to 18% of infants and children.

Atopic dermatitis has been considerably under-diagnosed due to the lack of approved effective systemic agents, and limitations of current topical agents.

Botanix executive director Matt Callahan said: “BTX 1204’s efficacy profile is in line with existing topical products whose treatment success rates are typically between 25-35%.

This combined with the excellent safety profile demonstrated to date underlines the potential for BTX 1204 to be a very safe and exciting new treatment for the millions of patients who suffer from this disease.”

View full BOT profile View Profile

Botanix Pharmaceuticals Ltd Timeline

Related Articles

cannabis
February 28 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
A paper plane about to be launched with the help of surgical scissors
November 13 2018
The voluntarily-suspended company is progressing an ongoing recapitalisation plan.
Cancer cells
February 07 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use